#CreativeDisruption: Latest & Future Technologies Impacting Life Sciences

This thought-leader discussion is about technologies that are disrupting the life sciences and health innovation sectors today & tomorrow About the Event The Creative Disruption Forum is a high-level, interactive gathering built for executive leaders, senior researchers, startup founders, and biotech investors. The Quantum Horizon Meets Real-World Science We are witnessing a transformative shift in health innovation. While emerging paradigms like quantum computing promise to fundamentally redefine how we process biological complexity in the future, biopharma leaders today need actionable, deployable technologies to de-risk pipelines, accelerate drug discovery, and improve clinical outcomes now. The Latest & Future Technologies Impacting Health Innovation and Life Sciences bridges the gap between tomorrow’s deep-tech horizons and today’s high-impact biological and computational breakthroughs. Hosted at ARC West London as a flagship London Life Sciences Week event, this interactive forum brings together biopharma executives, tech bio founders, investors, and academic leaders for unscripted, Chatham House Rules discussions on what is genuinely working, where the bottlenecks lie, and how to build scalable healthcare solutions. From physical molecule-to-protein target engagement (such as CETSA® platforms) and human-relevant New Approach Methodologies (NAMs) to real-world AI applications in lead optimization, this event delivers an unfiltered "boots on the ground" look at modern translational science. Why You Should Attend: Ground Your Strategy in Real-World Tech: Move beyond theoretical hype to evaluate proven technologies transforming R&D pipelines today—including next-gen sequencing (NGS), advanced cell & gene therapies, and biophysical target-engagement assays. De-Risk Your Clinical Pipeline: Discover how New Approach Methodologies (NAMs), organ-on-a-chip systems, and cellular shift assays are replacing legacy models, reducing Phase II/III failure rates, and delivering more efficacious molecules into the clinic. Unfiltered "Boots on the Ground" Insights: Hear directly from SME CEOs and biopharma R&D directors on integrating AI into discovery pipelines—sharing candid case studies on what works, what has failed, and how to avoid costly missteps. Connect Across the West Tech District: Engage directly with key anchors across West London’s innovation ecosystem, including Imperial College London, White City Innovation District, Paddington Life Sciences, Nexus, and ARC Group. Actionable Peer-to-Peer Workshops: Participate in interactive afternoon breakout sessions designed to co-create practical strategies for scaling deep-tech venture navigating regulatory pathways for NAMs, and optimizing R&D data. Who Should Attend: • Biopharma & Biotech Executives (CEOs, CSOs, CTOs, R&D Directors): Looking to de-risk discovery pipelines, adopt next-generation analytical platforms, and integrate computational tools effectively. • Tech Bio Founders & SME Leadership: Seeking real-world feedback on scaling ventures, securing investment, and overcoming wet-lab validation bottlenecks. • Venture Capitalists & Deep-Tech Investors: Eager to identify high-growth opportunities across both near-term biopharma technologies and long-term deep-tech frontiers. • Academic Researchers & Translational Scientists: Interested in commercializing spinouts and bridging the gap between basic research and clinical reality. • Clinical & Regulatory Leaders: Exploring FDA/MHRA roadmaps for NAM adoption, advanced diagnostics, and cell/gene therapy pathways. Draft Agenda 09:00 AM – 09:45 AM | Registration, Breakfast & Networking Arrival, registration, and informal networking over breakfast. 09:45 AM – 10:00 AM | Welcome and sponsor thank yous • Welcome: Deb Spencer (ARC West London) • Opening Address: Prof Tony Sedgwick & Graham Combe 10:00 AM – 10:45 AM | Opening Keynote Pael: The Future Promise of Quantum & Deep Tech in Healthcare - Adam Hammond, Head of Quantum EMEA, IBM, Anshu Bansal, Imperial College and London Quantum Cluster and Algorithmic (TBC). 10.45 AM - 11.30 am : De-Risking Pipelines — Target Engagement & New Approach Methodologies (NAMs) Unpacking intracellular target engagement in live cells (e.g., CETSA® and biophysical mass spectrometry) alongside microphysiological systems (organ-on-a-chip, 3D organoids) to confirm compound binding and improve translational success before clinical entry. • Keynote interviews including Michael Dabrowski, CEO, Pelago Bioscience AB 11:30 AM – 12:00 PM | Keynote Panel: What Is Being Funded Today vs. Tomorrow? Top VCs and life science investors discuss capital allocation across biological platforms, NAMs, and computational deep-tech, detailing how target-engagement data impacts valuation and Series funding. 12:00 PM – 12:30 PM | Refreshments & Networking Break 12:30 PM – 1.00 PM | Fireside Keynote Interview with Edwin Moses, Chairman, LabGenius, Avantium AV and Nanosyrinx. 1:00 PM – 1:30 PM | Boots on the Ground: SME & Startup CEO Showcase Fast-paced spotlight presentations and candid feedback from high-growth Tech Bio founders sharing practical case studies on hit identification, assay bottlenecks, and lessons learned from unsuccessful trials. 01:30 PM – 02:30 PM | Networking Lunch 02:30 PM – 03:45 PM | Interactive Workshop Breakouts • Track 1: Deploying AI & CETSA/Biophysical Assays in R&D Pipelines — Closing the gap between in silico predictions and physical binding. • Track 2: Translational Regulatory Pathways for NAMs & Organ-on-a-Chip — Working with regulators (FDA/MHRA) to reduce animal testing and speed up clinical entry. • Track 3: Scaling Deep Tech & Bio Ventures in West London — Infrastructure, lab space, capital, and ecosystem growth across the West Tech District. 03:45 PM – 04:30 PM | Workshop Closing & Executive Summary Synthesis of workshop takeaways, actionable strategies, and policy insights for sector leaders. 04:30 PM – 08:30 PM | Champagne Evening Reception, Keynote Talk & Networking - Adam Hammond, Head of Quantum, IBM Champagne drinks reception and evening keynote designed to build lasting partnerships across the tech, healthcare, and life sciences ecosystem. We promise that our #CreativeDisruption Forum will be like no other life sciences event or business network you have experienced. You will be walking out of the session inspired, educated and more connected. ADMISSION FEE for Service Companies such as CROs, CDMOs, Law Firms and Patent Attorneys, Consultancy Firms = £150 - ALL-INCLUSIVE ADMISSION FEE for Innovative Emerging Life Science Companies and Independent Consultants = £80 Investors can apply for free entry by writing to [email protected]. Collaborative Drug Discovery (CDD) provides an intuitive software suite extensively used by creative biologists and chemists working in academic, biotechnology and pharmaceutical settings. Their flagship product, CDD Vault, enables researchers to intuitively organize and analyze both biological and chemical data, and to collaborate with partners through a straightforward web interface. CDD helps scientists register entities, track inventory, manage assay data, capture experiments, calculate Structure-Activity Relationships (SAR), and mine their data for drug candidates. CDD was founded in 2004 and presently serves thousands of researchers doing drug discovery all around the world. Learn more atwww.collaborativedrug.com ARC West London is a dynamic hub for innovation, located on the scenic riverside in Hammersmith, at the heart of West Tech London – one of the UK’s fastest-growing life sciences and tech clusters. Designed for companies at every stage of their journey, the campus offers a seamless pathway from concept to commercial success. Start with Leap our incubator labs, run by Imperial Incubator, perfect for early-stage breakthroughs. Accelerate progress in Motherlabs, our fully serviced, flexible accelerator labs that removes the barriers to scaling.